Mitchell Tai

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The burgeoning pipeline for new biologic drugs has increased the need for high-throughput process characterization to efficiently use process development resources. Breakthroughs in highly automated and parallelized upstream process development have led to technologies such as the 250-mL automated mini bioreactor (ambr250™) system. Furthermore, developments(More)
  • 1